CTMX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
CytomX Therapeutics Inc (CTMX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. Positive analyst sentiment, strong clinical data, and a favorable options sentiment outweigh the weak financial performance in the latest quarter. The stock's current price of $5.49 offers potential upside based on analyst price targets of $10, representing an 82% increase.
The MACD is below zero and negatively contracting, indicating a bearish momentum. RSI is neutral at 50.132, and moving averages are converging, suggesting indecision. Key support is at $5.126, and resistance is at $5.864. Overall, the technical indicators show no strong trend but suggest the stock is stable near its pivot point.
Analysts have raised price targets to $10, citing strong clinical data and potential upside.
Hedge funds are significantly increasing their positions, with a 1979% rise in buying activity.
Upcoming clinical updates on metastatic colorectal cancer patients could further boost sentiment.
Insiders are selling, with a 359.35% increase in selling activity over the last month.
Financial performance in Q3 2025 showed significant declines in revenue (-82.16%), net income (-348.06%), and EPS (-228.57%).
In Q3 2025, CytomX reported a revenue drop of 82.16% YoY to $5.96M, a net income decline of 348.06% YoY to -$14.23M, and an EPS drop of 228.57% YoY to -$0.09. Gross margin remained strong at 100%. Despite weak financials, the company's clinical developments and potential pipeline success are driving optimism.
Analysts are highly optimistic, with multiple firms (Barclays, Piper Sandler, Guggenheim) raising price targets to $10 and maintaining Buy/Overweight ratings. Positive sentiment is driven by strong clinical data, particularly for Varseta-M in metastatic colorectal cancer, which has shown extraordinary antitumor activity.
